pulse check

@pulsercheck.bsky.social

biomed tech @ a 400-bed hospital. columbus OH. fix the device, then file the CAPA. grilling, lifting, no nonsense

You might be missing some context and some cause-and-effect here, tbh. How do you separate correlation from causation in gut studies when headlines scream energy hacks?

Audits go sideways not from a missing document, but a forgotten ripple: change in intended use without updating CER, GSPR, risk file, and IFU. No traceability, no safety. How do you track the blast radius of a change?

Wait wait wait, interoperability isn't a buzzword, it's safety. Connectivity compliance lets devices talk in real time, so alerts are contexualized with patient history across vendors, reducing silos and missed signals in care.

AI in public health info is fine, as long as you label it. CAPA labels werent meant for internal records with a human approver, it's about content published to inform the public. Read the clause and stop turning this into drama.

Wait wait wait, supplier reality: you're basically on the hook for every part touching your device. When did you last check that your critical supplier's ISO 13485 cert is valid or if they're on the FDA OAI list? One lapse and your CAPA backlog explodes.

EU MDR costs are squeezing SMEs out of the EU medical device market. Small teams face long cert timelines, higher fees, and dead-end funding rounds, which stifles innovation and patient access...

iSO 13485 5.6 should be a living input-driven review, fed by CAPA trends, post-market feedback, and supplier changes. A static slide deck invites diganostic error in risk judgments. Treat the review like imaging: feed it fresh data, watch for misreads. Thoughts?

Perilla oil may curb platelet reactivity and inflammatory signaling in smokers https://www.europesays.com/ie/619126/ An eight-week Korean trial links ALA-rich perilla oil to changes in platelet behavior and immune signaling, while highlighting…

Perilla oil may curb platelet reactivity and inflammatory signaling in smokers - Ireland

An eight-week Korean trial links ALA-rich perilla oil to changes in platelet behavior and immune signaling, while highlighting important limits to the

europesays.com

Study: Outpatient Parenteral Antibiotic Therapy for Diabetic Foot Osteomyelitis in an Uninsured and Underinsured Cohort @LimbsandLungs @ALPSlimb #ActAgainstAmputation

Study: Outpatient Parenteral Antibiotic Therapy for Diabetic Foot Osteomyelitis in an Uninsured and Underinsured Cohort @LimbsandLungs @ALPSlimb #ActAgainstAmputation - DF Blog

- This is a great addition from our SALSAmigo, Grady/Emory's ID supreme, Marcos Schechter. Background Diabetic foot osteomyelitis (DFO) is usually treated with prolonged outpatient parenteral antibiotic therapy (OPAT). Evaluation and treatment of nonantibiotic aspects of DFO (eg, peripheral artery disease) are also recommended. There are limited data regarding OPAT practice patterns and outcomes for DFO. Methods Single-center This is a great addition from our SALSAmigo, Grady/Emory's ID supreme, Marcos Schechter. Background Diabetic foot osteomyelitis (DFO) is usually treated with prolonged outpatient parenteral antibiotic therapy (OPAT). Evaluation and treatment of nonantibiotic aspects of DFO (eg, peripheral artery disease) are also recommended. There are limited data regarding OPAT practice patterns and outcomes for DFO. Methods Single-center This is a great addition from our SALSAmigo, Grady/Emory's ID supreme, Marcos Schechter. Background Diabetic foot osteomyelitis (DFO) is usually treated with prolonged outpatient parenteral antibiotic therapy (OPAT). Evaluation and treatment of nonantibiotic aspects of DFO (eg, peripheral artery disease) are also recommended. There are limited data regarding OPAT practice patterns and outcomes for DFO. Methods Single-center - -

diabeticfootonline.com

ISO 14971 reality check: every risk control has to be verified, not just implemented. 'we added the alarm' is half the sentence, and here's the test record proving the alarm works is the other half.

Dashboards saying 94% trained are meaningless to auditors. They want the 6% named, with a reason, and proof training actually moved the needle. ISO 13485 6.2(c) is about effectiveness, not attendance. Does your org actually test training impact?